J9329 Tislelizumab-jsgr - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Tislelizumab-jsgr

Brand Name:

Tevimbra

Strength:

1mg

HCPCS:

J9329

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Checkpoint Inhibitor

Minor Drug Class:

PD-1

Oral (Y/N):

No

FDA Approval Year:

2024

FDA Discontinuation Year:

CMS Effective Date:

Sept. 11, 2024

CMS Discontinuation Date:

Status:

In Use